Los Angeles Capital Management & Equity Research Inc. Has $26.65 Million Stake in Edwards Lifesciences Corporation (EW)

Los Angeles Capital Management & Equity Research Inc. lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 243,765 shares of the medical research company’s stock after selling 3,124 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.12% of Edwards Lifesciences Corporation worth $26,646,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of EW. ETF Managers Group LLC purchased a new stake in shares of Edwards Lifesciences Corporation during the second quarter valued at approximately $112,000. Shine Investment Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences Corporation during the second quarter valued at approximately $126,000. Cornerstone Advisors Inc. raised its stake in shares of Edwards Lifesciences Corporation by 25.1% during the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares during the period. Alexandria Capital LLC raised its stake in shares of Edwards Lifesciences Corporation by 1.7% during the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares during the period. Finally, MPS Loria Financial Planners LLC purchased a new stake in shares of Edwards Lifesciences Corporation during the second quarter valued at approximately $140,000. Institutional investors own 82.17% of the company’s stock.

WARNING: This article was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/11/15/los-angeles-capital-management-equity-research-inc-has-26-65-million-stake-in-edwards-lifesciences-corporation-ew.html.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded down $0.09 on Wednesday, hitting $105.15. The stock had a trading volume of 994,900 shares, compared to its average volume of 1,644,831. The firm has a market cap of $22,250.00, a P/E ratio of 29.15, a price-to-earnings-growth ratio of 1.89 and a beta of 0.46. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The business had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. Edwards Lifesciences Corporation’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 EPS. equities analysts predict that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.

A number of analysts recently issued reports on EW shares. BMO Capital Markets restated a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. William Blair restated an “outperform” rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th. Barclays PLC lifted their price target on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target for the company in a research note on Tuesday, July 18th. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $125.17.

In related news, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $111.81, for a total value of $2,119,917.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $100.93, for a total value of $3,320,597.00. The disclosure for this sale can be found here. Insiders sold a total of 139,580 shares of company stock worth $15,143,994 in the last quarter. 2.13% of the stock is owned by corporate insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply